CorVel Corporation — Form 10-Q Summary
Period clarification: The filing provided is for the quarter ended December 31, 2023, and the nine months then ended (CorVel fiscal Q3 2024), not 2022 Q3 as stated in the request metadata. Comparative figures are for the corresponding 2022 periods. Amounts are in U.S. dollars.
Business context and reporting period
CorVel provides managed-care and medical-cost-containment services, primarily for workers’ compensation, auto insurance, and group health claims. It reports one operating segment, managed care, with revenue from patient management and network solutions. The financial statements are unaudited.
Key financial metrics
| Metric | Three months ended Dec. 31, 2023 | Year-over-year change | Nine months ended Dec. 31, 2023 | Year-over-year change |
|---|---|---|---|---|
| Revenue | $202.3 million | +12.8% | $588.1 million | +10.3% |
| Gross profit / margin | $42.2 million / 20.8% | +4.5%; margin down from 22.5% | $128.3 million / 21.8% | +10.3%; margin unchanged |
| Income before taxes / margin | $22.4 million / 11.1% | +0.7%; margin down from 12.4% | $72.5 million / 12.3% | +17.0%; margin up from 11.6% |
| Net income | $17.1 million | +1.5% | $56.8 million | +17.8% |
| Diluted EPS | $0.99 | +3.1% | $3.27 | +19.8% |
| Cash from operations | Not presented for the quarter | — | $84.0 million | Up from $69.5 million |
Quarterly revenue comprised patient management of $131.8 million (+10.8%) and network solutions of $70.5 million (+16.7%). Nine-month revenue was $389.4 million (+10.2%) and $198.7 million (+10.4%), respectively. The filing reports no debt outstanding at December 31, 2023. Cash and cash equivalents were $107.0 million, versus $71.3 million at March 31, 2023; working capital was $106.0 million, versus $75.9 million. Total liabilities included $32.4 million of lease liabilities.
For the nine months, investing cash outflow was $19.2 million, primarily property and equipment purchases. Financing cash outflow was $29.1 million, including $36.5 million of share repurchases and $7.1 million of option-exercise proceeds. Capital expenditures were $19.2 million.
Material changes and management commentary
- Management attributed revenue growth mainly to increased activity with existing customers, including higher TPA-related patient management revenue and growth in network solutions. New claims rose 1.6% in the quarter and 3.2% over nine months year over year.
- Quarterly cost of revenues rose 15.2%, faster than revenue, reflecting business growth and a 10% increase in salaries alongside 9.3% higher average field-operations headcount. Gross margin consequently declined 1.7 percentage points. General and administrative expense rose 9.2% in the quarter, but was 9.8% of revenue versus 10.1% a year earlier.
- For nine months, cost of revenues grew in line with revenue; G&A increased 2.6%, improving to 9.5% of revenue from 10.2%. Lower diluted share counts, partly reflecting repurchases, contributed to EPS growth.
- Operating cash flow increased year over year, which management attributed primarily to higher net income and the timing of accrued payroll. Share-repurchase spending was lower than in the prior-year period.
Outlook, risks, contingencies, and unusual items
- No specific revenue, earnings, or margin guidance is provided. Management says cash, ongoing operating cash flow, and option-exercise proceeds should fund operations, capital needs, and the current repurchase program for at least the next 12 months. Repurchases may be reduced or stopped if income or cash flow declines.
- Management noted that 2022 occupational injuries remained below 2019 levels, despite increasing from 2021, and that fewer claims can affect demand. It also cited competition, customer retention, wage and benefit inflation, medical inflation, staffing, regulatory changes, cybersecurity, and technology execution as risks.
- Management reported modifying the work-in-process estimate for its post-pay commercial health product to better reflect completion earlier in the review cycle; this benefited December-quarter network-solutions results. The filing does not quantify the benefit.
- Management warned that inflation could materially affect pricing and operating expenses in future periods. Ordinary-course litigation is not expected by the company to result in material payments. The filing also discloses approximately $5.0 million of operating-lease commitments for leases not yet commenced.
- The company repurchased 177,484 shares for $36.5 million during the nine months and, after quarter-end, repurchased another 12,122 shares for $2.8 million. It had approximately 1.0 million shares remaining under the program at December 31, 2023.
Important facts for investors to verify
- Confirm the reporting-period mismatch: the supplied filing covers December 31, 2023, rather than 2022 Q3.
- Assess whether revenue growth can continue and whether quarterly gross-margin compression reverses, particularly given labor-cost growth and the unquantified work-in-process estimate benefit.
- Review receivables and collections: net accounts receivable increased to $92.7 million, including unbilled receivables of $38.5 million, from $26.6 million at March 31, 2023.
- Monitor cash conversion, payroll accrual timing, capital spending, and the pace and price of future share repurchases.
- Evaluate exposure to claim volumes, customer renewals and insourcing, staffing and inflation, regulatory changes, and cybersecurity incidents.